Drugs / MIB-626
MIB-626
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07013591 | Jun 2026 → Oct 2028 expected | coronary artery disorder | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIB-626 | “NMN (MIB-626) 1,000 mg PO twice daily, administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively” NCT07013591 ↗ |
| Known as | nicotinamide mononucleotide | “oral nicotinamide mononucleotide (NMN) administration” NCT07013591 ↗ |
| Known as | NMN | “An orally-administered stable crystalline tablet formulation of NMN” NCT07013591 ↗ |
| Route | Oral | “An orally-administered stable crystalline tablet formulation of NMN” NCT07013591 ↗ |